Since the emergence of the selective Eg5 inhibitor monastrol (suppressing its driving capacity by specifically inhibiting the ATPase vitality of the motor domain), plenty of practices have been made to investigate other promising Eg5-aimed small molecules to provide more choices for anti-mitotic-based tumor chemotherapy. This evidence concerns the gene KIF11 and neoplasm.